Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8494, S8894 and S9346)
Year: 2012
Type: article
Abstract: PURPOSE: Frequent prostate specific antigen testing for screening and monitoring prostate cancer has led to significant stage migration. We evaluated whether overall survival in hormone naïve patients with metastatic prostate cancer has improved during the era of prostate specific antigen use. We also assessed whether any patient subsets benefited differentially during this period. MATERIALS AND METHODS: We compared overall survival in 3 sequential phase III trials of 3,096 men with hormone naïve, metastatic prostate cancer who received similar androgen deprivation therapy, including 2 trials performed before the prostate specific antigen era (S8494 and S8894) and the other done during this era (S9346). Overall survival was adjusted for patient and disease risk factors in the latter 2 trials. Subgroups were evaluated by interactions of risk factors with trial. RESULTS: Median overall survival was 30 months in S8494, 33 months in S8894 and 49 months in S9346. Adjusting for risk factors, there was a 22% lower risk of death in S9346 than in S8894 (HR 0.78, 95% CI 0.70, 0.87, p <0.001). The improvement in overall survival was greater in black American men (test of interaction p = 0.008). In S8494 and S8894 median survival for black men was 27 months, and 34 and 35 months for nonblack men, respectively. This racial difference disappeared in S9346 with overall survival of 48 and 49 months in black and nonblack men, respectively. CONCLUSIONS: Adjusting for risk factors, overall survival was significantly improved in the post-prostate specific antigen era trial. However, it cannot be concluded that this was attributable only to prostate specific antigen monitoring. Black men now have overall survival comparable to that of white men. Current estimates of survival should be used to design new trials in this population.
Source: The Journal of Urology
Institutions: Fred Hutch Cancer Center, University of Michigan, University of Washington, Johns Hopkins Hospital, University of California, San Francisco, University of Wisconsin–Madison, Eastern Virginia Medical School, University of Colorado Denver, Comprehensive Cancer Centers of Nevada, Wayne State University, The University of Texas at San Antonio Health Science Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: G1033243903, KINGS COUNTY MINORITY BASED CLINICAL ONCOLOGY PROGRAM, G117886320, G1194379741, G1202672505, G1216887118, SOUTHWEST ONCOLOGY GROUP, G1257575315, G1268312386, G1312097577, G1331445602, G1343089328, SAN JOAQUIN VALLEY COMMUNITY CLINICAL ONCOLOGY PROGRAM, G1375689152, G1392966516, Columbus Community Clinical Oncology Program (Columbus CCOP), G1469275664, G1545560008, G1549000524, G157871073, G1646027999, COOPERATIVE STUDY OF CANCER CHEMOTHERAPY, G1790576020, G1794831901, G1911575068, G1958973285, G1985252453, G2043432835, G2057923966, SOUTHWEST ONCOLOGY GROUP, Scott & White Community Clinical Oncology Program, G217018306, G2201816905, G2237949143, G2276667821, G2320693132, G2345882982, G2419449687, G2435896781, G2485941414, ALLEGHENY COMMUNITY CLINICAL ONCOLOGY PROGRAM, G2562936776, G2646278872, G268786457, G2750730928, COLUMBIA UNIVERSITY SOUTHWEST ONCOLOGY GROUP PROGRAM, G2779306227, G2780474162, G278654822, Ozark Health Ventures, LLC dba Cancer Research for the Ozarks, REGULATION OF MITOGENIC CYTOKINE INDUCED APOPTOSIS, GRAND RAPIDS CLINICAL ONCOLOGY PROGRAM, SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER, G3126600779, G313314762, G3242537740, Southeast Cancer Control Consortium, Inc, G3295642875, G3334379738, G3337849518, G345775953, G3484997517, G3497039781, G3521018462, City of Hope Southwest Oncology Group Clinical Trials, G36541222, G3710026009, G3737421695, G379387698, COMMUNITY CLINICAL ONCOLOGY PROGRAM, G3939550896, G398851121, G4110529384, G413878341, G425646771, G42679306, G4271794948, Southwest Oncology Group, CENTRAL LOS ANGELES COMMUNITY CLINICAL ONCOLOGY PROGRAM, G4292856267, G444114835, Southwest Oncology Group, G4499432180, G4527800867, G461382845, SOUTHWEST ONCOLOGY GROUP, G4719029039, COMMUNITY CLINICAL ONCOLOGY PROGRAM, G5187432406, G5264753430, G5566132837, COMMUNITY CLINICAL ONCOLOGY PROGRAM, G591690631, SOUTHWEST ONCOLOGY GROUP, G6211207823, Gulf Coast MBCCOP, G6723594983, SOUTHWEST ONCOLOGY GROUP, G6782300252, G6943608702, G7222907299, G7230571265, CENTRAL ILLINOIS COMMUNITY CLINICAL ONCOLOGY PROGRAM, G7520596819, G758084519, Virginia Mason Community Clinical Oncology Program, SOUTHWEST ONCOLOGY GROUP, G7860541851, G7926913928, G8006406963, G8036334546, G8116866424, G8156375866, G8413228103, G860872252, G869870603, SOUTHWEST ONCOLOGY GROUP, G8740717309, G8777682367, PARTICIPATE AS MEMBER OF SOUTHWEST ONCOLOGY GROUP, G8937348795, G924713883, G933283670, G937543590, G945297361, G971274320
OpenAlex ID: W1989683537